Skip Ribbon Commands
Skip to main content
Clin Asst Prof Tan Jing Ying Tira

Clin Asst Prof Tan Jing Ying Tira

BSc (Hons), MBBS (UK), MRCP (UK)

Senior Consultant

National Cancer Centre Singapore

Specialty: Medical Oncology

Clinical Interest: Breast

Conditions Treated by this Doctor:
Breast Cancer.

Clinical Appointments

  • Senior Consultant Division of Medical Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore

Academic Appointments

  • Clinical Asst Professor


Dr Tira Tan is a Senior Consultant Medical Oncologist at the National Cancer Centre Singapore with a clinical focus in the treatment of breast cancers and early phase drug development. Dr Tan chairs the pre-operative and young women’s breast cancer programs at NCCS and is the divisional deputy director of research as well as a primary and co-investigator on many early and late phase studies specifically in novel therapeutics and treatment strategies in triple negative breast cancer.


  • Oct 2015 Specialist Certificate in Medical Oncology, Ministry of Health, Singapore
  • Apr 2014 MRCP (UK), Royal College of Physicians, UK
  • Jun 2006 MBBS (UK), Imperial College London, UK
  • Jun 2004 BSc (Hons), Imperial College London, UK

Professional Appointments and Committee Memberships

​2021 – Current   Deputy Director of Research, Division of Medical Oncology, NCCS
2021 – Current   Clinical Assistant Professor, Duke-NUS Medical School, Singapore
2017 – Current  Senior Consultant, Division of Medical Oncology, National Cancer Centre Singapore
2014 – Current  Clinical Lecturer, Yong Yoo Lin School of Medicine, Singapore
Current -  Member of American Society of Clinical Oncology
Current -  Member of European Society of Medical Oncology


​2021 NMRC Research Training Fellowship
2020 NMRC New Investigator Grant
2019 Singapore Cancer Society Cancer Research Grant
2018 NCCS Fellowship Grant
2015 Best Registrar Award, SingHealth Residency, Singapore
2014 SingHealth Best Junior Doctor Award – Best Registrar Award
2013 American Society of Clinical Oncology Merit Award

Research Interests


  • Yee MS, Pavitt DV, Tan T, Venkatesan S, Godsland IF, Richmond W, Johnston DG. Lipoprotein separation in a novel iodixanol density gradient, for composition, density, and phenotype analysis. J Lipid Res. 2008 Jun;49(6):1364-71. doi: 10.1194/jlr.D700044-JLR200. Epub 2008 Mar 12. 
  • Wang YT, Lim HY, Tai D, Krishnamoorthy TL, Tan T, Barbier S, Thumboo J. The impact of irritable bowel syndrome on health-related quality of life: a Singapore perspective. BMC Gastroenterol. 2012 Aug 9;12:104. doi: 10.1186/1471-230X-12-104. 
  • Jain A, Tan TJ, Tan DS. Carcinoma of unknown primary site. N Engl J Med. 2014 Nov 20;371(21):2039. doi: 10.1056/NEJMc1411384#SA1. No abstract available. 
  • Singapore Cancer Network (SCAN) Guidelines for the Use of Systemic Therapy in Advanced Non-Small Cell Lung Cancer. Singapore Cancer Network (SCAN) Lung Cancer Workgroup. Ann Acad Med Singapore. 2015 Oct;44(10):449-62 
  • Rajasekaran T, Tan T, Ong WS, Koo KN, Chan L, Poon D, Roy Chowdhury A, Krishna L, Kanesvaran. Comprehensive Geriatric Assessment (CGA) based risk factors for increased caregiver burden among elderly Asian patients with cancer. J Geriatr Oncol. 2016 Apr 7. pii: S1879-4068(16)30021-2. doi: 10.1016/j.jgo.2016.03.003. [Epub ahead of print] 
  • Tan T, Ong WS, Rajasekaran T, Koo KN, Chan LL, Poon D, Chowdhury AR, Krishna L, Kanesvaran R. Identification of Comprehensive Geriatric Assessment Based Risk Factors for Malnutrition in Elderly Asian Cancer Patients. PloS one. 2016 May 27;11(5):e0156008. 

Research Trials

  1. A study protocol for HEalth-Related quality of life-intervention in survivors of Breast and other cancers experiencing cancer-related fatigue using TraditionAL Chinese Medicine: the HERBAL trial. 
  2. Perspective and Supportive Care Needs of Asian Breast Cancer Patients Enrolled in a Preoperative Therapy Program – PreSCella
  3. A Phase I Study of BTRC4017A in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers (NCT03448042)
  4. A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) (NCT04009681)
  5. A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) (NCT04622319)
  6. Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study (NCT04589845)
  7. A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer (NCT03975647)
  8. Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) (NCT03167619)